JCM, Vol. 8, Pages 1646: Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease

JCM, Vol. 8, Pages 1646: Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease:
JCM, Vol. 8, Pages 1646: Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's Disease
Journal of Clinical Medicine doi: 10.3390/jcm8101646
Authors: Ribaldone Caviglia Abdulle Pellicano Ditto Morino Fusaro Saracco Astegiano
The response to treatment with biologic drugs, in patients with Crohn’s disease, could be associated with changes in gut microbiota composition. The aim of our study was to analyse the modification of microbiota during adalimumab therapy in patients with Crohn’s disease. We performed a prospective study in patients with Crohn’s disease analysing gut microbiota before start of adalimumab therapy (T0) and after six months of therapy (T1). Among the 20 included patients, the phylum Proteobacteria fell from 15.7 ± 3.5% at T0 to 10.3 ± 3.4% at T1 (p = 0.038). Furthermore, the trend in relation to therapeutic success was analysed. Regarding bacterial phyla, Proteobacteria decreased in patients in whom therapeutic success was obtained, passing from a value of 15.8% (± 4.6%) to 6.8 ± 3.1% (p = 0.049), while in non-responder patients, percentages did not change (T0 = 15.6 ± 5.7%, T1 = 16.8 ± 7.6%, p = 0.890). Regarding the Lachnospiraceae family, in patients with normalization of C reactive protein six 6 months of adalimumab therapy, it increased from 16.6 ± 3.1% at T0 to 23.9 ± 2.6% at T1 (p = 0.049). In conclusion, in patients who respond to Adalimumab therapy by decreasing inflammation, there is a trend of intestinal eubiosis being restored.